Flaherty Lab Publications
22. Scott, J. A.; Soto-Velasquez, M.; Hayes, M. P.; LaVigne, J. E.; Miller, H. R.; Kaur, J.; Ejendal, K. F. K.; Watts, V. J.*; Flaherty, D. P.* Optimization of a pyrimidinone series for selective inhibition of Ca2+/calmodulin-stimulated adenylyl cyclase 1 activity for treatment of chronic pain. Journal of Medicinal Chemistry, 2022, accepted. https://doi.org/10.1021/acs.jmedchem.1c01759
21. Giovannuzzi, S.; Hewitt, C. S.; Nocentini, A.; Capasso, C.; Costantino, G.; Flaherty, D. P.; Supuran, C. T. Inhibition studies of bacterial a-carbonic anhydrases with phenols. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 666-671. https://doi.org/10.1080/14756366.2022.2038592
20. Hewitt, C. S.; Das, C.; Flaherty, D. P.* Rational development and characterization of a ubiquitin variant with selectivity for ubiquitin C-terminal hydrolase L3. Biomolecules, 2021, 12, 62. https://doi.org/10.3390/biom12010062
19. Giovannuzzi, S.; Hewitt, C. S.; Nocentini, A.; Capasso, C.; Flaherty, D. P.*; Supuran, C. T.* Coumarins effectively inhibit bacterial a-carbonic ahydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 37, 333-338. https://doi.org/10.1080/14756366.2021.2012174
18. Abutaleb, N. S.; Elhassanny, A. E. M.; Nocentini, A.; Hewitt, C. S.; Elkashif, A.; Cooper, B. R.; Supuran, C. T.; Seleem, M. N.*, Flaherty, D. P.* Repurposing FDA-Approved sulfonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 37, 51-61. DOI: 10.1080/14756366.2021.1991336
17. Giovannuzzi, S.; Abutaleb, N. S.; Hewitt, C. S.; Carta, F.; Nocentini, A.; Seleem, M. N.; Flaherty, D. P.*; Supuran, C. T.* Dithiocarbamates effectively inhibit the alpha-carbonic anhydrase from Neisseria gonorrhoeae. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 37, 1-8. DOI: 10.1080/14756366.2021.2012174
16. Flaherty, D. P.*; Seleem, M. N.; Supuran, C. T. Bacterial Carbonic Anhydrases: Underexploited antibacterial therapeutic targets. Future Medicinal Chemistry, 2021, 13, 1619 - 1622. DOI: 10.4155/fmc-2021-0207
15. Nocentini, A.; Hewitt, C. S.; Mastrolorenzo, M. D.; Flaherty, D. P.*; Supuran, C. T.* Anion inhibition studies of the alpha-carbonic anhydrase from Neisseria gonorrhoeae. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1061 - 1066. DOI: 10.1080/14756366.2021.1929202
14. Hewitt, C.S; Abutaleb, N.S.; Elhassanny, A.E.M.; Nocentini, A.; Cao, X.; Amo, D.P.; Youse, M.S.; Holly, K.J.; Marapaka, Anil Kumar; An, W.; Kaur, J.; Krabill, A.D.; Elkashif, A.; Elgammal, Y.; Graboski, A.L.; Supuran, C.T.; Saleem, M.N.*, Flaherty, D.P.* Structure-activity relationship studies of acetazolamide-based inhibitors with activity against Neisseria gonorrhoeae. ACS Infectious Diseases, 2021, 7, 1969-1984. DOI: 10.1021/acsinfecdis.1c00055.
13. Chojnacki, M.; Cao, X.; Flaherty, D.P.* and Dunman, P.D.* Optimization of 2-acylaminocycloalkythiophene derivatives for activity against Staphylococcus aureus. Antibiotics, 2021, 10, 369
12. Krabill, A.D.; Chen, H.; Hussain, S.; Hewitt, C.S.; Imhoff, R.D.; Muli, C.S.; Das, C.; Galardy, P.J.; Wendt, M.K.; Flaherty, D.P.; Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1. Molecules, 2021, 26(5), p.1227.
11. Sheedlo, M. J.; Kenny, S.; Podkoytov, I. S.; Brown, K.; Ma, J.; Iyer, S.; Hewitt, C. S.; Arbough, T.; Mikhailovskii, O.; Flaherty D. P.; Wilson, M. A.; Skrynnikov, N. R.; Das, C. Insights into Ubiquitin Product Release in Hydrolysis Catalyzed by the Bacterial Deubiquitinase SdeA. Biochemistry,2021, just accepted, DOI:10.1021/acs.biochem.0c00760
10. Abutaleb, N. S.; Elhassanny, A. E. M.; Flaherty, D. P.; Seleem, M. N. In vitro and in vivo activities of carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ, 2021, 9, e11059
9. Abutaleb, N. S.; Elkashif, A.; Flaherty, D. P.; Seleem, M. N. In vivo antibacterial activity of acetazolamide. Antimicrobial Agents and Chemotherapy, 2021, 65, e01715-20. DOI: 10.1128/AAC.01715-20
8. Hewitt, C. S.; Krabill, A. D.; Das, C.; Flaherty, D. P. Development of Ubiquitin Variants with Selectivity for Ubiquitin C-Terminal Hydrolase Deubiquitinase. Biochemistry, 2020, 59 (37), 3447 – 3462
7. Kaur, J.; Cao, X.; Abutaleb, N. S.; Elkashif, A.; Graboski, A. L.; Krabill, A. D.; AbdelKhalek, A. H.; An, W.; Bhardwaj, A.; Seleem, M. N.; Flaherty, D. P. Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus. Journal of Medicinal Chemistry, 2020, 63(17), 9540-9562. DOI:10.1021/acs.jmedchem.0c00734.
6. Chojnacki, M.; Cao, X.; Young, M.; Fritz, R.; Dunman, P. M.; Flaherty, D. P. Optimization of 4-substituted Benzensulfonamide Scaffold to Reverse Acinetobacter baumannii Serum-Adaptive Efflux Associated Antibiotic Tolerance. ChemMedChem, 2020, 15 (18), 1731-1740. DOI: 10.1002/cmdc/202000328.
5. Saboo S.; Kestur, U.S.; Flaherty, D.P., Taylor, L.S. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition. Molecular Pharmaceutics, 2020, 17(4), 1261-1275.
4. Krabill, A.D., Chen, H., Hussain, S., Feng, C., Abdullah, A., Hewitt, C.S.; Das, C., Aryal, U.K., Post, C.B., Wendt, M.K., Galardy, P.J. and Flaherty, D.P.Ubiquitin C-terminal hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine-Based Inhibitor. ChemBioChem,2020, 21, 712-722.